, Thrombophilia testing and venous thrombosis, vol.377, pp.1177-1787, 2017.
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies, Lupus, vol.20, pp.206-218, 2011. ,
,
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome, Blood, vol.132, pp.1365-1371, 2018. ,
Detection of lupus anticoagulant in the era of direct oral anticoagulants, Autoimmun. Rev, vol.16, pp.173-178, 2017. ,
Frequent False-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin, Int. J. Lab. Hematol, vol.36, 2014. ,
Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants, Thromb. Res, vol.165, pp.101-106, 2018. ,
, Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/ antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis, vol.7, pp.1737-1740, 2009.
Guidelines on the investigation and management of antiphospholipid syndrome, Br. J. Haematol, vol.157, pp.47-58, 2012. ,
, , 2014.
Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing, Am. J. Clin. Pathol, vol.124, pp.586-593, 2005. ,
,
The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation aassays for the diagnosis of hemostasis disorders, J. Thromb. Haemost, vol.13, pp.2087-2092, 2015. ,
The adsorption of dabigatran is as efficient as addition of Idarucizumab to neutralize the drug in routine coagulation assays, Int. J. Lab. Hematol, vol.40, pp.442-447, 2018. ,
Simple method for removing DOACs from plasma samples, Thromb. Res, vol.163, pp.117-122, 2018. ,
,
Evaluation of the DOAC Stop procedure to overcome the Effect of DOACs on Several thrombophilia screening tests, Thromb. Haemost. Open, vol.2, pp.202-209, 2018. ,
Removal of DOACs from plasma: performance comparison and pre-analytical considerations of three different devices, p.220, 2018. ,
Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin, J. Thromb ,
, , vol.15, pp.273-283, 2017.
De Laat, for the subcommittee on lupus anticoagulant/antiphospholipid antibodies, Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH, J. Thromb. Haemost, vol.16, pp.809-813, 2018. ,
An update of laboratory assessment of direct oral anticoagulants (DOACs), Int. J. Lab. Hematol, vol.41, pp.33-39, 2019. ,
The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples, Pathology, vol.48, pp.60-71, 2016. ,
Lupus-anticoagulant testing at NOAC trough levels, Thromb. Haemost, vol.116, pp.235-240, 2016. ,
Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study, Eur. Heart. J, vol.38, pp.2431-2439, 2017. ,
START-Laboratory Register, Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillations: results observed in four anticoagulation clinics, Thromb. Res, vol.137, pp.178-183, 2016. ,
Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting, Thromb. Haemost, vol.117, pp.1700-1704, 2017. ,
, Thrombophilia testing and venous thrombosis, vol.377, pp.2297-2298, 2017.
,
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome ,
, , pp.295-306, 2006.
Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time, J. Thromb. Haemost, vol.9, pp.1657-1659, 2011. ,
The taipan snake venom time can be used to detect lupus anticoagulant in patients treated by rivaroxaban, Int. J. Lab. Hem, vol.39, pp.60-63, 2016. ,
Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests, Clin. Chem. Lab. Med, vol.50, pp.1601-1605, 2012. ,
The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples, Pathology, vol.47, pp.355-364, 2015. ,